Tesaglitazar AstraZeneca.
AstraZeneca (formerly Astra) is developing tesaglitazar, a peroxisome proliferator-activated receptor (PPAR) agonist, for the potential treatment of diabetes and insulin resistance [275466], [377656]. Early phase clinical trials for both of these indications were ongoing in July 2002 [459440].
Davis
Tim
T
University of Western Australia, Department of Medicine, Fremantle Hospital, PO Box 480, Fremantle, Western Australia 6959, Australia. tdavis@cyllene.uwa.edu.au